Volker Möbus

5.1k total citations
117 papers, 2.2k citations indexed

About

Volker Möbus is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Volker Möbus has authored 117 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 40 papers in Cancer Research and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Volker Möbus's work include Breast Cancer Treatment Studies (37 papers), Cancer Treatment and Pharmacology (30 papers) and Ovarian cancer diagnosis and treatment (23 papers). Volker Möbus is often cited by papers focused on Breast Cancer Treatment Studies (37 papers), Cancer Treatment and Pharmacology (30 papers) and Ovarian cancer diagnosis and treatment (23 papers). Volker Möbus collaborates with scholars based in Germany, United States and Switzerland. Volker Möbus's co-authors include R. Kreienberg, Christoph Thomssen, Michael Untch, K. Pollow, Jens Huober, Andreas du Bois, F. Jänicke, Sibylle Loibl, Nadia Harbeck and Axel Hinke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Volker Möbus

106 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Volker Möbus Germany	26	1.2k	587	493	422	312	117	2.2k
Jermaine Coward Australia	23	1.2k 1.0×	354 0.6×	704 1.4×	318 0.8×	380 1.2×	87	2.3k
John W. Moroney United States	19	874 0.7×	493 0.8×	656 1.3×	310 0.7×	438 1.4×	49	2.5k
Mayu Yunokawa Japan	25	1.1k 0.9×	373 0.6×	511 1.0×	256 0.6×	482 1.5×	140	2.1k
Jean‐Sébastien Frenel France	26	1.4k 1.2×	708 1.2×	801 1.6×	295 0.7×	809 2.6×	188	2.7k
Christian Schem Germany	24	913 0.8×	839 1.4×	790 1.6×	211 0.5×	402 1.3×	124	2.2k
Lars Hanker Germany	25	1.0k 0.9×	513 0.9×	827 1.7×	724 1.7×	340 1.1×	100	2.4k
Sharad Ghamande United States	22	770 0.6×	216 0.4×	579 1.2×	476 1.1×	230 0.7×	114	1.7k
Malgorzata Tuxen Denmark	18	687 0.6×	318 0.5×	394 0.8×	947 2.2×	282 0.9×	33	1.8k
Frauke Bentzien United States	10	665 0.6×	298 0.5×	821 1.7×	288 0.7×	522 1.7×	12	2.1k
Deolinda Pereira Portugal	26	1.3k 1.1×	514 0.9×	937 1.9×	1.3k 3.1×	323 1.0×	86	2.8k

Countries citing papers authored by Volker Möbus

Since Specialization

Citations

This map shows the geographic impact of Volker Möbus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Volker Möbus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Volker Möbus more than expected).

Fields of papers citing papers by Volker Möbus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Volker Möbus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Volker Möbus. The network helps show where Volker Möbus may publish in the future.

Co-authorship network of co-authors of Volker Möbus

This figure shows the co-authorship network connecting the top 25 collaborators of Volker Möbus. A scholar is included among the top collaborators of Volker Möbus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Volker Möbus. Volker Möbus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matikas, Alexios, Andri Papakonstantinou, Sibylle Loibl, et al.. (2024). Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial. The Lancet Regional Health - Europe. 49. 101162–101162. 2 indexed citations

Mackelenbergh, Marion van, Fenja Seither, Volker Möbus, et al.. (2022). Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer. 166. 185–201. 9 indexed citations

Reinisch, Mattea, Michael Untch, Toralf Reimer, et al.. (2020). 86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial. Annals of Oncology. 31. S44–S44. 1 indexed citations

Laakmann, Elena, Isabell Witzel, U. Grzyska, et al.. (2016). Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. International Journal of Molecular Sciences. 17(10). 1615–1615. 20 indexed citations

Gluz, Oleg, C Liedtke, Jens Huober, et al.. (2016). Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Annals of Oncology. 27(6). 1035–1040. 10 indexed citations

Bekes, Inga, Thomas W. P. Friedl, Volker Möbus, et al.. (2016). Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?. Molecular Cancer. 15(1). 13–13. 40 indexed citations

Möbus, Volker. (2016). Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients. Breast Care. 11(1). 8–12. 246 indexed citations

Erber, Ramona, Oleg Gluz, Nils Brünner, et al.. (2015). Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Research and Treatment. 150(2). 279–288. 10 indexed citations

Minckwitz, Gϋnter von, Bettina Conrad, Toralf Reimer, et al.. (2015). A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer. 121(20). 3639–3648. 43 indexed citations

10.

Noeding, S, Helmut Forstbauer, Angelika Ober, et al.. (2014). Gain2: Adjuvant Phase III Trial Comparing an Intensified Dose-Dense Adjuvant Therapy with Enpc Compared with a Dose-Dense, Dose-Adapted Therapy with Dtec Dtdocetaxel in Patients with Primary Breast Cancer and a High Risk of Recurrence. Annals of Oncology. 25. iv90–iv90.

11.

Möbus, Volker, et al.. (2013). Male and Female Physicians in Hospital Gynaecology Departments - Analysis of the Impact of “Feminisation” from the Viewpoint of Medical Directors. Geburtshilfe und Frauenheilkunde. 73(1). 53–58. 8 indexed citations

12.

Konecny, Gottfried E., Giovanni M. Pauletti, Michael Untch, et al.. (2010). Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Research and Treatment. 120(2). 481–489. 43 indexed citations

13.

Minckwitz, Gϋnter von, Volker Möbus, Bettina Conrad, et al.. (2009). 0157 GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer. The Breast. 18. S59–S59. 1 indexed citations

14.

Huober, Jens, Christian Jackisch, Michael Untch, et al.. (2006). Adjuvanter Einsatz von Trastuzumab (Herceptin®) beim primären Mammakarzinom - aktuelle Datenlage und Bewertung der Stellungnahme des Kompetenz Centrums Onkologie des MDK Nordrhein. Zentralblatt für Gynäkologie. 128(1). 30–37. 2 indexed citations

15.

Müller, Volkmar, Isabell Witzel, Günter Köhler, et al.. (2004). Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer. Breast Cancer Research and Treatment. 86(1). 9–18. 58 indexed citations

16.

Reinartz, Silke, H. Schlebusch, Jens Huober, et al.. (2004). Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125. Clinical Cancer Research. 10(5). 1580–1587. 97 indexed citations

17.

Möbus, Volker & R. Kreienberg. (1998). Systemische Therapie des Zervixkarzinoms. Der Onkologe. 4(2). 167–173. 1 indexed citations

18.

Volm, T., Volker Möbus, & R. Kreienberg. (1998). New Aromatase Inhibitors. Oncology Research and Treatment. 21(6). 460–466. 7 indexed citations

19.

Pollow, K., et al.. (1992). Dihydrospirorenone (ZK30595): A novel synthetic progestagen-characterization of binding to different receptor proteins. Contraception. 46(6). 561–574. 44 indexed citations

20.

Möbus, Volker, et al.. (1992). Amniozentese zur pränatalen Diagnostik aus psychischer Indikation. Geburtshilfe und Frauenheilkunde. 52(4). 225–229. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact